Sirna to Supply GSK with RNAi-based Therapeutics for Respiratory Disease | GenomeWeb

NEW YORK, May 4 (GenomeWeb News) - Sirna Therapeutics said today that it will provide GlaxoSmithKline with siRNA therapeutics against asthma, respiratory syncytial virus, chronic obstructive pulmonary disease, and allergic rhinitis as part of its ongoing collaboration with the pharmaceutical company.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.